Lucid Diagnostics (NASDAQ:LUCD) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD – Free Report) in a research report report published on Monday, Benzinga reports. Needham & Company LLC currently has a $2.50 price objective on the stock. Separately, Cantor Fitzgerald lowered their target price on shares of Lucid Diagnostics from $3.80 to […]

Related Keywords

United States , ,Lucid Diagnostics Company Profile ,Lucid Diagnostics Inc ,Cantor Fitzgerald ,Needham Company ,Lucid Diagnostics ,Free Report ,Diagnostics Stock Down ,Get Free Report ,Diagnostics Inc ,Esoguard Esophageal ,Esocheck Esophageal Cell ,Lucid Diagnostics Daily ,